Navigation Links
Drugs from the sea: New discoveries in marine biomedicine
Date:5/13/2011

Substances produced by living organisms found in natureso-called "natural products"have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

To raise awareness about the vast potential of marine- and natural product-based biotechnology in the discovery and development of new drugs, the New York Academy of Sciences and the marine-based drug development company Zeltia S.A. are hosting a symposium, "New Frontiers in Marine Drug Discovery" at the New York Academy of Sciences Conference Center on May 20, 2011. This symposium will address the newly discovered and tremendous potential that the biodiversity of the marine ecosystem offers as a source for new therapeutically useful compounds, from the early stage drug discovery perspective of academia and the clinical therapy development perspective of industry.

The event will showcase recent technological improvements in natural product chemistry; review the landscape of marine-derived compoundsboth approved drugs and those in the development and trial stages; and explore examples of pioneering efforts, failures and successes in the translation of small molecules of natural marine origin into first-in-class and life-changing therapies for metastatic ovarian and metastatic breast cancer, among other diseases.

WHAT: A Scientific Symposium: New Frontiers in Marine Drug Discovery

WHO:

  • William Fenical, PhD, Director, Scripps Institution of Oceanography
  • Shirley Pomponi, PhD, President and CEO, Harbor Branch Oceanographic Institution
  • Juli M. Trtanj, Director, Oceans and Human Health Initiative, NOAA National Ocean Service
  • Roberto Weinmann, PhD, COO PharmaMar USA, a company of the Zeltia Group

WHEN: Friday May 20, 2011 | 8:00 AM - 7:00 PM

WHERE:
The New York Academy of Sciences
7 World Trade Center, 250 Greenwich St., 40th floor, New York, NY


'/>"/>

Contact: Marta Murcia
mmurcia@nyas.org
212-298-8641
New York Academy of Sciences
Source:Eurekalert

Related biology news :

1. Cholesterol-lowering drugs and the effect on muscle repair and regeneration
2. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
3. Discovering drugs, biofuels in tropical seas
4. Academy participates in project to discover drugs, biofuels in tropical seas
5. European researchers harness unique properties of boron to develop new drugs and diagnostics
6. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
7. Moderate use averts failure of type 2 diabetes drugs in animal model
8. Montana State University researchers find gene that regulates molds resistance to drugs
9. MSU researcher studies ties between cholesterol drugs, muscle problems
10. New technique eliminates toxic drugs in islet transplant in diabetic mice
11. REGiMMUNE receives $12 million in grants to develop transplant and allergy drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology: